Nanomicellar carriers for targeted delivery of anticancer agents

Therapeutic Delivery

Volumn 5, Issue 1, 2014, Pages 53-68

  Zhang, Xiaolan ^a   Huang, Yixian ^a   Li, Song ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; EMBELIN; NANOCARRIER; PACLITAXEL; POLYMER;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CRITICAL MICELLE CONCENTRATION; DRUG DELIVERY SYSTEM; MICELLE; MOLECULAR WEIGHT; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TISSUE SPECIFICITY;

EID: 84890922315     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.135     Document Type: Review

References (153)

1. Rawat M, Singh D, Saraf S, Saraf S. Nanocarriers: promising vehicle for bioactive drugs. Biol. Pharm. Bull. 29, 1790-1798 (2006).
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-36 (2000).
3. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 47, 2486-2493 (1987).
4. Alkhamis KA, Allaboun H, Al-Momani WY. Study of the solubilization of gliclazide by aqueous micellar solutions. J. Pharm. Sci. 92, 839-846 (2003).
5. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24, 1-16 (2007).
6. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631-651 (2002).
7. Haag R, Kratz F. Polymer therapeutics: concepts and applications. Angew. Chem. Int. Ed. 45, 1198-1215 (2006).
8. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm. Res. 24, 1029-1046 (2007).
9. Mi Y, Liu Y, Feng SS. Formulation of docetaxel by folic acid-conjugated d-a-tocopheryl polyethylene glycol succinate 2000 (vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. Biomaterials 32, 4058-4066 (2011).
10. Danson S, Ferry D, Alakhov V et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer. 90, 2085-2091 (2004).
11. Matsumura Y, Hamaguchi T, Ura T et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer. 91, 1775-1781 (2004).
12. Kim TY, Kim DW, Chung JY et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Cancer Res. 10, 3708-3716 (2004).
13. Hamaguchi T, Doi T, Eguchi-Nakajima T et al. Phase I study of NK012, a novel SN-38- incorporating micellar nanoparticle, in adult patients with solid tumors. Clin. Cancer Res. 16, 5058-5066 (2010).
14. Kato K, Chin K, Yoshikawa T et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest. New Drugs. 30, 1621-1627 (2012).
15. Plummer R, Wilson RH, Calvert H et al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br. J. Cancer. 104, 593-598 (2011).
16. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JF, Hennink WE. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm. Res. 27, 2569-2589 (2010).
17. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283-318 (2001).
18. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 47, 113-131 (2001).
19. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release. 73, 137-172 (2001).
20. Torchilin VP. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 58, 1532-1555 (2006).
21. Torchilin VP. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv. Drug Deliv. Rev. 54, 235-252 (2002).
22. Lu J, Huang Y, Zhao W et al. Design and characterization of PEG-derivatized vitamin E as a nanomicellar formulation for delivery of paclitaxel. Mol. Pharm. 10, 2880-2890 (2013).
23. Huang Y, Lu J, Gao X et al. PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel. Bioconjug. Chem. 23, 1443-1451 (2012).
24. Lu J, Huang Y, Zhao W et al. PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers. Biomaterials 34, 1591-1600 (2013).
25. Zhang X, Lu J, Huang Y et al. PEG-farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel. Bioconjug. Chem. 24, 464-472 (2013).
26. Zhang P, Lu J, Huang Y et al. Design and evaluation of a PEGylated lipopeptide equipped with drug-interactive motifs as an improved drug carrier. AAPS J. 10(1), 187-198 (2013).
27. Zhang Y, Zhuo RX. Synthesis and in vitro drug release behavior of amphiphilic triblock copolymer nanoparticles based on poly (ethylene glycol) and polycaprolactone. Biomaterials 26, 6736-6742 (2005).
28. Avgoustakis K, Beletsi A, Panagi Z et al. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int. J. Pharm. 259, 115-127 (2003).
29. Duan K, Zhang X, Tang X et al. Fabrication of cationic nanomicelle from chitosan-graft-polycaprolactone as the carrier of 7-ethyl-10- hydroxy-camptothecin. Colloids Surf. B Biointerfaces 76, 475-482 (2010).
30. Bae Y, Kataoka K. Intelligent polymeric micelles from functional poly(ethylene glycol)-620 poly(amino acid) block copolymers. Adv. Drug Delivery Rev. 61, 768-784 (2009).
31. Xiao K, Luo J, Fowler WL et al. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 30, 6006-6016 (2009).
32. Luo J, Xiao K, Li Y et al. Well-defined, sizetunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. Bioconjug. Chem. 21, 1216-1224 (2010).
33. Xiao K, Luo J, Li Y, Lee JS, Fung G, Lam KS. PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. J. Control. Release. 155, 272-281 (2011).
34. Gao ZG, Lukyanov AN, Singhal A, Torchilin VP. Diacyl polymer micelles as nanocarriers for poorly soluble anticancer drugs. Nano Lett. 2, 979-982 (2002).
35. Li M, Chrastina A, Levchenko T, Torchilin VP. Micelles from poly(ethylene glycol)- phosphatidyl ethanolamine conjugates (PEG-PE) as pharmaceutical nanocarriers for poorly soluble drug camptothecin. J. Biomed. Nanotechnol. 1, 190-195 (2005).
36. Sawant RR, Torchilin VP. Multifunctionality of lipid-core micelles for drug delivery and tumour targeting. Mol. Membr. Biol. 27, 232-246 (2010).
37. Lukyanov AN, Hartner WC, Torchilin VP. Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. J. Control. Release. 94, 187-193 (2004).
38. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. 49, 6288-6308 (2010).
39. Jo Y, van der Vlies AJ, Gantz J et al. RAFT Homo- and copolymerization of N-acryloyl-morpholine, piperidine, and azocane and their self-assembled structures. Macromolecules 41, 1140-1150 (2008).
40. Torchilin VP, Trubetskoy VS, Whiteman KR, Caliceti P, Ferruti P, Veronese FM. New synthetic amphiphilic polymers for steric protection of liposomes in vivo. J. Pharm. Sci. 84, 1049-1053 (2005).
41. Maruyama K, Okuizumi S, Ishida O, Yamauchi H, Kikuchi H, Iwatsuru M. Phosphatidyl polyglycerols prolong liposome circulation in vivo. Int. J. Pharm. 111, 103-107 (1994).
42. Takeuchi H, Kojima H, Toyoda T, Yamamoto H, Hino T, Kawashima Y. Prolonged circulation time of doxorubicin-loaded liposomes coated with a modified polyvinyl alcohol after intravenous injection in rats. Eur. J. Pharm. Biopharm. 48, 123-129 (1999).
43. Yuan F, Dellian M, Fukumura et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752-3756 (1995).
44. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392 (1986).
45. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65, 271-284 (2000).
46. Moghimi SM, Davis SS. Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection. Drug Carrier Syst. 11, 31-59 (1994).
47. Cabral H, Matsumoto Y, Mizuno K et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 6, 815-823 (2011).
48. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 9, 1909-1915 (2009).
49. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263, 1600-1603 (1994).
50. Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol. Membr. Biol. 27, 286-298 (2010).
51. Sawant RR, Jhaveri AM, Torchilin VP. Immunomicelles for advancing personalized therapy. Adv. Drug Deliv. Rev. 64, 1436-1446 (2012).
52. Sawant RR, Sawant RM, Torchilin VP. Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity. Eur. J. Pharm. Biopharm. 70, 51-57 (2008).
53. Xiao K, Li Y, Lee JS et al. 'OA02' peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res. 72, 2100-2110 (2012).
54. Lee ES, Na K, Bae YH. Polymeric micelle for tumor pH and folate-mediated targeting. J. Control. Release 91, 103-113 (2003).
55. Xu W, Siddiqui IA, Nihal M et al. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials 34, 5244-5253 (2013).
56. John CS, Vilner BJ, Geyer BC, Moody T, Bowen WD. Targeting S receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors. Cancer Res. 59, 4578-4583 (1999).
57. Zhang Y, Huang Y, Zhang P, Gao X, Gibbs RB, Li S. Incorporation of a selective S-2 receptor ligand enhances uptake of liposomes by multiple cancer cells. Int. J. Nanomed. 7, 4473-4485 (2012).
58. MauriceT, Su TP. The pharmacology of S-1receptors. Pharmacol. Ther. 124, 195-206 (2009).
59. Sawant RR, Jhaveri AM, Koshkaryev A, Qureshi F, Torchilin VP. The effect of dual ligand-targeted micelles on the delivery and efficacy of poorly soluble drug for cancer therapy. J. Drug Target. 21, 630-638 (2013).
60. Tomlinson R, Klee M, Garrett S, Heller J, Duncan R, Brocchini S. Pendent chain functionalized polyacetals that display pH-dependent degradation: a platform for the development of novel polymer therapeutics. Macromolecules 35, 473-480 (2002).
61. Toncheva V, Schacht E, Ng SY, Barr J, Heller J. Use of block copolymers of poly(ortho esters) and poly(ethylene glycol) micellar carriers as potential tumor targeting systems. J. Drug Target. 11, 345-353 (2003).
62. Bae Y, Fukushima S, Harada A, Kataoka K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew. Chem. Int. Ed. Engl. 42, 4640-4643 (2003).
63. Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur. J. Pharm. Biopharm. 71, 431-444 (2009).
64. Lee HJ, Ponta A, Bae Y. Polymer nanoassemblies for cancer treatment and imaging. Ther. Deliv. 1, 803-817 (2010).
65. Hu J, Miura S, Na K, Bae YH. pH-responsive and charge shielded cationic micelle of poly(l-histidine)-block-short branched PEI for acidic cancer treatment. J. Control. Release. 172, 69-76 (2013).
66. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J. Nutr. 134, 489-492 (2004).
67. Huang H, Zhang X, Yu J et al. Fabrication and reduction-sensitive behavior of polyion complex nano-micelles based on PEG-conjugated polymer containing disulfide bonds as a potential carrier of anti-tumor paclitaxel. Colloids Surf. B Biointerfaces 110, 59-65 (2013).
68. Wang K, Luo GF, Liu Y et al. Redox-sensitive shell cross-linked PEG-polypeptide hybrid micelles for controlled drug release. Polym. Chem. 3, 1084-1090 (2012).
69. Wei H, Zhuo RX, Zhang XZ. Design and development of polymeric micelles with cleavable links for intracellular drug delivery. Prog. Polym. Sci. 38, 503-535 (2013).
70. Shklar G, Schwartz J, Trickler DP, Niukian K. Regression by vitamin E of experimental oral cancer. J. Natl. Cancer Inst. 78, 987-992 (1987).
71. Malafa MP, Neitzel LT. Vitamin E succinate promotes breast cancer tumor dormancy. J. Surg. Res. 93, 163-170 (2000).
72. Malafa MP, Fokum FD, Mowlavi A, Abusief M, King M. Vitamin E inhibits melanoma growth in mice. Surgery 131, 85-91 (2002).
73. Malafa MP, Fokum FD, Smith L, Louis A. Inhibition of angiogenesis and promotion of melanoma dormancy by vitamin E succinate. Ann. Surg. Oncol. 9, 1023-1032 (2002).
74. Dong LF, Swettenham E, Eliasson J et al. Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: the role of oxidative stress. Cancer Res. 67, 11906-11913 (2007).
75. Dalen H, Neuzil J. a-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kB activation. Br. J. Cancer. 88, 153-158 (2003).
76. Crispen PL, Uzzo RG, Golovine K et al. Vitamin E succinate inhibits NF-kB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. Prostate 67, 582-590 (2007).
77. Wang XF, Witting PK, Salvatore BA, Neuzil J. Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway. Biophys. Res. Commun. 326, 282-289 (2005).
78. Weber T, Lu M, Andera L et al. Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo. Clin. Cancer Res. 8, 863-869 (2002).
79. Barnett KT, Fokum FD, Malafa MP. Vitamin E succinate inhibits colon cancer liver metastases. J. Surg. Res. 106, 292-298 (2002).
80. Ripoll EA, Rama BN, Webber MM. Vitamin E enhances the chemotherapeutic effects of adriamycin on human prostatic carcinoma cells in vitro. J. Urol. 136, 529-531 (1986).
81. Yin Y, Ni J, Chen M, Guo Y, Yeh S. RRR-a-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects. Clin. Cancer Res. 15, 190-200 (2009).
82. Kanai K, Kikuchi E, Mikami S et al. Vitamin E succinate induced apoptosis and enhanced chemosensitivity to paclitaxel in human bladder cancer cells in vitro and in vivo. Cancer Sci. 101, 216-223 (2010).
83. Constantinides PP, Han J, Davis SS. Advances in the use of tocols as drug delivery vehicles. Pharm. Res. 23, 243-255 (2006).
84. Youk HJ, Lee E, Choi MK et al. Enhanced anticancer efficacy of a-tocopheryl succinate by conjugation with polyethylene glycol. J. Control. Release 107, 43-52 (2005).
85. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26, 2713-2722 (2005).
86. Win KY, Feng SS. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(d,l-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials 27, 2285-2291 (2006).
87. Ma YD, Zheng Y, Liu KX et al. Nanoparticles of poly(lactide-i-glycolide)- d-a-tocopheryl polyethylene glycol 1000 succinate random copolymer for cancer treatment. Nanoscale Res. Lett. 6, 1161-1169 (2010).
88. Wang J, Sun J, Chen Q et al. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance. Biomaterials 33, 6877-6888 (2012).
89. Muthu MS, Kulkarni SA, Xiong J, Feng SS. Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int. J. Pharm. 421, 332-340 (2011).
90. Marom M, Haklai R, Ben-Baruch G, Marciano D, Egozi Y, Kloog Y. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J. Biol. Chem. 270, 22263-22270 (1995).
91. Cao N, Feng SS. Doxorubicin conjugated to d-a-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials 29, 3856-3865 (2008).
92. Anbharasi V, Cao N, Feng SS. Doxorubicin conjugated to d-a-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. J. Biomed. Mater. Res. A 94, 730-743 (2010).
93. Zhang Z, Feng SS. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 27, 4025-4033 (2006).
94. Pan J, Feng SS. Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials 29, 2663-2672 (2008).
95. Mu L, Feng SS. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm. Res. 20, 1864-1872 (2003).
96. Mu L, Feng SS. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol). J. Control. Release 80, 129-144 (2002).
97. Feng S, Huang G. Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J. Control. Release 71, 53-69 (2001).
98. Muthu MS, Kulkarni SA, Raju A, Feng SS. Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials 33, 3494-3501 (2012).
99. Zhai G, Wu J, Zhao X et al. A liposomal delivery vehicle for the anticancer agent gossypol. Anticancer Res. 28, 2801-2805 (2008).
100. Parmentier J, Becker MM, Heintz U, Fricker G. Stability of liposomes containing bio-enhancers and tetraether lipids in simulated gastro-intestinal fluids. Int. J. Pharm. 405, 210-217 (2011).
101. Xu H, Abe H, Naito M et al. Efficient dispersing and shortening of super-growth carbon nanotubes by ultrasonic treatment with ceramic balls and surfactants. Adv. Powder Technol. 21, 551-555 (2010).
102. Mi Y, Zhao J, Feng SS. Vitamin E TPGS prodrug micelles for hydrophilic drug delivery with neuroprotective effects. Int. J. Pharm. 438, 98-106 (2012).
103. Gupta R, Sharma AK, Sharma MC, Gupta RS. Antioxidant activity and protection of pancreatic b-cells by embelin in streptozotocin-induced diabetes. J. Diabetes. 4, 248-256 (2012).
104. Bhandari U, Jain N, Pillai KK. Further studies on antioxidant potential and protection of pancreatic beta-cells by Embelia ribes in experimental diabetes. Exp. Diabetes Res. 2007, 15803 (2007).
105. Chitra M. Sukumar E, Suja V, Devi CS. Antitumor, anti-inflammatory and analgesic property of embelin, a plant product. Chemotherapy 40, 109-113 (1994).
106. Mahendran S, Badami S, Ravi S, Thippeswamy BS, Veerapur VP. Antioxidant analgesic and anti-inflammatory properties of new ninhydrin adduct of embelin. Pharmaceutical Chem. J. 45, 547-551 (2011).
107. Mahendran S, Thippeswamy BS, Veerapur VP, Badami S. Anticonvulsant activity of embelin isolated from Embelia ribes. Phytomedicine 18, 186-188 (2011).
108. Kumara Swamy HM, Krishna V, Shankarmurthy K et al. Wound healing activity of embelin isolated from the ethanol extract of leaves of Embelia ribes burm. J. Ethnopharmacol. 109, 529-534 (2007).
109. Kumar GK, Dhamotharan R, Kulkarni NM, Honnegowda S, Murugesan S. Embelin ameliorates dextran sodium sulfate-induced colitis in mice. Int. Immunopharmacol. 11, 724-731 (2011).
110. Singh D, Singh R, Singh P, Gupta RS. Effects of embelin on lipid peroxidation and free radical scavenging activity against liver damage in rats. Basic Clin. Pharmacol. Toxicol. 105, 243-248 (2009).
111. Li Y, Li D, Yuan S et al. Embelin-induced MCF-7 breast cancer cell apoptosis and blockade of MCF-7 cells in the G2/M phase via the mitochondrial pathway. Oncol. Lett. 5, 1005-1009 (2013).
112. Dai Y, Qiao L, Chan KW et al. Peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of Embelin on colon carcinogenesis. Cancer Res. 69, 4776-4783 (2009).
113. Danquah M, Li F, Duke CB 3rd, Miller DD, Mahato RI. Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm. Res. 26, 2081-2092 (2009).
114. Mori T, Doi R, Kida A et al. Effect of the XIAP inhibitor embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J. Surg. Res. 142, 281-286 (2007).
115. Nikolovska-Coleska Z, Xu L, Hu Z et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J. Med. Chem. 47, 2430-2440 (2004).
116. Tamm I, Kornblau SM, Segall H et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 6, 1796-1803 (2000).
117. Chen J, Nikolovska-Coleska Z, Wang G, Qiu S, Wang S. Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. Bioorg. Med. Chem. Lett. 16, 5805-5808 (2006).
118. Kim SW, Kim SM, Bae H et al. Embelin inhibits growth and induces apoptosis through the suppression of Akt/mTOR/S6K1 signaling cascades. Prostate 73, 296-305 (2013).
119. Heo JY, Kim HJ, Kim SM et al. Embelin suppresses STAT3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase PTEN. Cancer Lett. 308, 71-80 (2011).
120. Kalyan Kumar G, Dhamotharan R, Kulkarni NM, Mahat MY, Gunasekaran J, Ashfaque M. Embelin reduces cutaneous TNF-a level and ameliorates skin edema in acute and chronic model of skin inflammation in mice. Eur. J. Pharmacol. 662, 63-69 (2011).
121. Joy B, Sivadasan R, Abraham TE et al. Lysosomal destabilization and cathepsin B contributes for cytochrome c release and caspase activation in embelin-induced apoptosis. Mol. Carcinog. 49, 324-336 (2010).
122. Husain K. Francois RA, Yamauchi T, Perez M, Sebti SM, Malafa MP. Vitamin E d-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-kb activation in pancreatic cancer. Mol. Cancer Ther. 10, 2363-2372 (2011).
123. Ahn KS, Sethi G, Aggarwal BB. Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kB (NF-kB) signaling pathway leading to suppression of NF-kB-regulated antiapoptotic and metastatic gene products. Mol. Pharmacol. 71, 209-219 (2007).
124. Park SY, Lim SL, Jang HJ et al. Embelin induces apoptosis in human glioma cells through inactivating NF-kb. J. Pharmacol. Sci. 121, 192-199 (2013).
125. Danquah M, Duke CB, Patil R et al. Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer. Pharm. Res. 29, 2079-2091 (2012).
126. Allensworth JL, Aird KM, Aldrich AJ, Batinic-Haberle I, Devi GR. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells. Mol. Cancer Ther. 11, 1518-1527 (2012).
127. Edderkaoui M, Odinokova I, Ohno I et al. Ellagic acid induces apoptosis through inhibition of nuclear factor kb in pancreatic cancer cells. World J. Gastroenterol. 14, 3672-3680 (2008).
128. Che YF, Zhang DY, Ye F, Wu BY, Jiang B. Combination of flavopiridol and embelin effectively inhibit cell growth in hepatocellular carcinoma depending on regulatory relationship between CDK6 and XIAP. Med. Chem. Res. 21, 3369-3375 (2012).
129. Minakshi MS, Mulch SA, Deul KB, Nayna MJ. Herbosomes: herbo-phospholipid complex an approach for absorption enhancement. J. Incl. Phenom. Macrocycl. Chem. 69, 139-147 (2011).
130. Hu CM, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv. 1, 323-334 (2010).
131. Marciano D, Ben-Baruch G, Marom M et al. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth. J. Med. Chem. 38, 1267-1272 (1995).
132. Haklai R, Weisz MG, Elad G et al. Dislodgment and accelerated degradation of Ras. Biochemistry 37, 1306-1314 (1998).
133. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682-4689 (1989).
134. Kloog Y, Cox AD. RAS inhibitors: potential for cancer therapeutics. Mol. Med. Today. 6, 398-402 (2000).
135. Blum R, Kloog Y. Tailoring Ras-pathway - inhibitor combinations for cancer therapy. Drug Resist.Updat. 8, 369-380 (2005).
136. Cox AD, Der CJ. Ras family signaling: therapeutic targeting. Cancer Biol. Ther. 1, 599-606 (2002).
137. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer. 11, 761-774 (2011).
138. Rotblat B, Ehrlich M, Haklai R, Kloog Y. The Ras inhibitor farnesyl thiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Meth. Enzymol. 439, 467-489 (2008).
139. Jansen B, Schlagbauer-Wadl H, Kahr H et al. Novel Ras antagonist blocks human melanoma growth. Proc. Natl Acad. Sci. USA 96, 14019-14024 (1996).
140. Niv H, Gutman O, Henis YI, Kloog Y. Membrane interactions of a constitutively active GFP-Ki-Ras 4B and their role in signaling. Evidence from lateral mobility studies. J. Biol. Chem. 274, 1606-1613 (1999).
141. Kloog Y, Cox AD, Sinensky M. Concepts in Ras-directed therapy. Expert Opin. Investig. Drugs 8, 2121-2140 (1999).
142. Laheru D, Shah P, Rajeshkumar NV et al. Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer. Investig. New Drugs 30, 2391-2399 (2012).
143. Goldberg L, Israeli R, Kloog Y. FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice. Cell Death Dis. 3, 284 (2012).
144. Biran A, Brownstein M, Haklai R, Kloog Y. Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. Int. J. Cancer. 128, 691-701 (2011).
145. Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, Kloog Y. The Ras inhibitor S-trans,trans-farnesyl thiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin. Cancer Res. 8, 555-565 (2002).
146. Aizman E, Mor A, Levy A, George J, Kloog Y. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes. Oncotarget 3, 144-157 (2012).
147. Mor A, Aizman E, Kloog Y. Celecoxib enhances the anti-inflammatory effects of farnesylthiosalicylic acid on T cells independent of prostaglandin E (2) production. Inflammation 35, 1706-1714 (2012).
148. Kraitzer A, Kloog Y, Haklai R, Zilberman M. Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitro. J. Pharm. Sci. 100, 133-149 (2011).
149. Kim JY, Kim S, Pinal R., Park K. Hydrotropic polymer micelles as versatile vehicles for delivery of poorly water-soluble drugs. J. Control. Release 152, 13-20 (2011).
150. Huh KM, Lee SC, Cho YW, Lee J, Jeong LH, Park K. Hydrotropic polymer micelle system for delivery of paclitaxel. J. Control. Release 3, 59-68 (2005).
151. Saravanakumar G, Min KH, Min DS et al. Hydrotropic oligomer conjugated glycol chitosan as a carrier of paclitaxel: synthesis, characterization, and in vivo biodistribution. J. Control. Release 16, 210-217 (2009).
152. Gao X, Huang Y, Makhov AM et al. Nanoassembly of surfactants with interfacial drug-interactive motifs as tailor-designed drug carriers. Mol. Pharm. 10, 187-198 (2013).
153. Epperly MW,Goff JP,Li S et al. Intraesophageal administration of GS-nitroxide (JP4-039) protects against ionizing irradiation-induced esophagitis. In Vivo 24, 811-819 (2010)